DYAX 12.78 Dyax Corp $DYAX Hit a 52 week high of 1

DYAX 12.78 Dyax Corp $DYAX Hit a 52 week high of 13.17 Closing the day 11/07/14 at 12.78 -0.27 -2.07% With a day low of 12.54 and a total volume of 1,148,675.

DYAX Recent Posts: http://investorshangout.com/Dyax-DYAX-53955/

DYAX Dyax Corp Recent Headline News

Why Dyax (DYAX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:42AM CST
Dyax's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
DYAX: 12.78 (-0.27)

Can Dyax (DYAX) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:49AM CST
Dyax possess a positive long term growth rate and favorable Zacks Rank
DYAX: 12.78 (-0.27)

Dyax Shares Up 62.1% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 62.07% as of today's recent price of $12.29.
DYAX: 12.78 (-0.27)

Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930
Business Wire - Mon Nov 03, 6:30AM CST
Dyax Corp. (NASDAQ: DYAX) today announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema (HAE) attacks.
DYAX: 12.78 (-0.27)

BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 320.75 (-2.72), AMAG: 34.95 (+0.83), BIND: 9.22 (+0.48), DYAX: 12.78 (-0.27)

Will Dyax (DYAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:04AM CDT
Will Dyax (DYAX) Continue to Surge Higher?
DYAX: 12.78 (-0.27)

Dyax beats Street 3Q forecasts
Automated Insights - Tue Oct 28, 4:48PM CDT
BURLINGTON, Mass. (AP) _ Dyax Corp. (DYAX) on Tuesday reported a loss of $816,000 in its third quarter.
DYAX: 12.78 (-0.27)

Dyax Corp. Announces Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:01PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers -including the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 12.78 (-0.27)

Shares of DYAX Up 41.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 27, 9:38AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 41.60% as of today's recent price of $10.74.
DYAX: 12.78 (-0.27)

Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 14.13 (-0.07), BCRX: 10.46 (+0.14), NBIX: 18.58 (-0.10), ONTY: 1.60 (-0.07), DYAX: 12.78 (-0.27)

Dyax Has Returned 31.6% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Oct 20, 9:12AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 31.58% as of today's recent price of $9.98.
DYAX: 12.78 (-0.27)

Dyax Corp. to Host Third Quarter 2014 Earnings Call and Webcast
Business Wire - Tue Oct 14, 7:00AM CDT
Dyax Corp. (NASDAQ YAX) will host a webcast and conference call, including an open question and answer session, Tuesday, October 28, 2014. During the call, management will discuss the Company's financial results for the third quarter 2014 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 12.78 (-0.27)

Dyax Up 25.6% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Fri Oct 10, 5:12PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 25.64% as of today's recent price of $9.53.
DYAX: 12.78 (-0.27)

35.7% Return Seen to Date on SmarTrend Dyax Call (DYAX)
Comtex SmarTrend(R) - Fri Oct 03, 4:43PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on May 27th, 2014 at $7.59. In approximately 4 months, Dyax has returned 35.66% as of today's recent price of $10.29.
DYAX: 12.78 (-0.27)

Dyax Up 36.5% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Fri Sep 26, 10:57AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on May 27th, 2014 at $7.59. In approximately 4 months, Dyax has returned 36.45% as of today's recent price of $10.35.
DYAX: 12.78 (-0.27)

Dyax Corp. to Participate in the Leerink Partners Rare Disease Roundtable
Business Wire - Thu Sep 25, 6:00AM CDT
Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Leerink Partners Rare Disease Roundtable being held October 1, 2014 at the Le Parker Meridien Hotel in New York City and is scheduled to present at 11:30am (ET) that day. The Company will provide a corporate update on the Company's key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 12.78 (-0.27)

Dyax Corp. Highlights Recent Progress in Licensing and Funded Research Portfolio
Business Wire - Mon Sep 22, 6:12AM CDT
Dyax Corp. (NASDAQ YAX) today highlighted recent progress and upcoming milestones in its Licensing and Funded Research Portfolio (LFRP), including, most recently, licensee Eli Lilly and Company's announcement of the fourth positive Phase 3 study outcome for CYRAMZA(TM) (ramucirumab). Product candidates in Dyax's LFRP are eligible for royalties on the first ten years of commercial sales from each antibody program, as well as certain milestone payments. The LFRP currently has 10 product candidates in clinical trials and multiple preclinical programs.
LLY: 66.60 (-0.36), DYAX: 12.78 (-0.27)

Dyax Shares Up 40.0% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Fri Sep 19, 9:35AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ YAX) on May 27th, 2014 at $7.59. In approximately 4 months, Dyax has returned 40.01% as of today's recent price of $10.62.
DYAX: 12.78 (-0.27)

Dyax Corp. Announces Issuance of Two Key U.S. Patents for DX-2930
Business Wire - Mon Sep 15, 6:00AM CDT
Dyax Corp. (NASDAQ: DYAX) today announced that the U.S. Patent and Trademark Office (USPTO) has issued two new patents related to DX-2930, an investigational fully human monoclonal antibody inhibitor of active plasma kallikrein. One patent, assigned U.S. Patent No. 8,816,055, contains claims covering the specific sequence of DX-2930, and the other, assigned U.S. Patent No. 8,822,653, contains claims covering monoclonal antibodies that bind to the active form of human plasma kallikrein and do not bind human pre-kallikrein. Both patents are expected to provide coverage for DX-2930 until at least 2032.
DYAX: 12.78 (-0.27)